Physician profile
Ami Lam
NPI 1558759670
$16,133.28
in general payments reported to CMS, 2019-2025
58 companies · $517 in 2025
The $517 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,968 · 2022: $4,887 · 2023: $4,216 · 2024: $2,546 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,880 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,879.77 |
| Education | $398.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,128.22 | 2021-2025 | Tagrisso, Imfinzi, Enhertu |
| Lilly USA, LLC | $1,091.78 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $1,031.29 | 2021-2023 | Tukysa, Padcev, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $957.46 | 2021-2024 | Opdivo |
| Daiichi Sankyo INC. | $926.40 | 2021-2025 | Enhertu, Injectafer, Vanflyta |
| Incyte Corporation | $781.62 | 2021-2023 | Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $749.88 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $747.56 | 2021-2025 | |
| Janssen Biotech, INC. | $747.47 | 2021-2024 | Tecvayli, Erleada, Darzalex |
| Celgene Corporation | $590.47 | 2021-2024 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $546.33 | 2021-2024 | |
| Puma Biotechnology, INC. | $523.75 | 2021-2024 | Nerlynx |
| Eisai INC. | $501.97 | 2021-2024 | |
| Amgen INC. | $487.59 | 2021-2023 | Lumakras |
| Astellas Pharma US INC | $359.36 | 2021-2024 | Xtandi |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.